CHOLANGIOCARCINOMA
TREATMENT
Cholangiocarcinoma has been transformed by molecular oncology more than perhaps any other GI cancer. FGFR2 fusions, IDH1 mutations, HER2 amplification โ each has a targeted therapy. Chinese centres treat the highest volume of biliary tract cancer glo
analyticsAt a Glance
- check_circleCholangiocarcinoma (bile duct cancer) is often diagnosed at an advanced stage
- check_circleFGFR2 inhibitors (pemigatinib, infigratinib) are approved for FGFR2-fusion positive disease
- check_circleIDH1 inhibitor ivosidenib is approved for IDH1-mutant advanced cholangiocarcinoma
- check_circleImmunotherapy combinations and clinical trials are the main options for unresectable cases
What This Means for Patients
First-line: gemcitabine/cisplatin+durvalumab (TOPAZ-1). FGFR2 fusion iCCA: pemigatinib (35.5% ORR, FIGHT-202), futibatinib. IDH1-mutant: ivosidenib (ClarIDHy trial OS benefit). HER2-amplified: trastuzumab, T-DXd, disitamab vedotin (RC48). MSI-H: checkpoint immunotherapy. FOLFOX second-line (ABC-06).
Key Insights
Understanding this topic is critical for rare cancer treatment planning and access decisions.
Clinical Relevance
Directly impacts treatment selection, molecular profiling decisions, and access to targeted therapies and clinical trials for rare cancer patients.
For Patients
Knowledge enables better-informed questions for oncologists, more productive specialist consultations, and active participation in treatment decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Tumour-agnostic approvals transformed rare cancer treatment access
- Comprehensive genomic profiling identifies actionable alterations across tumour types
- Chinese academic centres provide cost-accessible specialist rare cancer expertise
Limitations
- Not all rare cancers carry targetable molecular alterations
- Some rare cancers genuinely have no effective treatment currently
- Specialist expertise concentrated at a small number of centres globally
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Navigating Rare Cancer Treatment?
CancerFax connects rare cancer patients with specialist centres, molecular profiling, targeted therapy access, and clinical trial opportunities at Chinese academic centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.